Aleksandra Filipovic, Chief Medical Officer at Gallop Oncology, shared a post by Sharing Progress in Cancer Care (SPCC), adding:
“Join the SPCC Webinar on HER2-Positive Breast Cancer: Pathological and Molecular Insights
We invite the oncology community to join this upcoming SPCC (Sharing Progress in Cancer Care) webinar dedicated to the pathological and molecular features of HER2-positive breast cancer — a cornerstone topic in modern oncology.
HER2 remains one of the most important therapeutic targets in breast cancer, and yet, its biology continues to unfold with new layers of complexity. From molecular heterogeneity and resistance mechanisms to novel diagnostic and therapeutic strategies, our expert panel will explore how these emerging insights are reshaping clinical practice and precision oncology.
As moderator, I look forward to guiding a rich discussion that bridges cutting-edge science with real-world impact.
Don’t miss this opportunity to engage with leading experts and deepen your understanding of the evolving HER2 landscape.”
Quoting Sharing Progress in Cancer Care (SPCC)‘s post:
“Happening today!
Join us for the next session of the EU-funded Definitive Trial project.
Gain insights from leading experts on how tumour biology, molecular profiling, and diagnostic innovation are shaping personalised treatment strategies in early breast cancer.
28 October 2025 | 18:00 CET
View the live webinar (free of charge).
Aleksandra Filipovic MD Ph.D. Mattia Rediti Esther Sanfeliu
Funded by the European Union – Horizon Europe Grant Agreement No. 101136953.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.
This work has also received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).”
